Mostrar el registro sencillo del ítem
| dc.contributor.author | Martínez-Sanz, Javier | |
| dc.contributor.author | Díaz-alvarez, Jorge | |
| dc.contributor.author | Rosas, Marta | |
| dc.contributor.author | Ron, Raquel | |
| dc.contributor.author | Iribarren, José-Antonio | |
| dc.contributor.author | Bernal-Morell, Enrique | |
| dc.contributor.author | Gutiérrez, Félix | |
| dc.contributor.author | Sancho, Andres-Ruiz | |
| dc.contributor.author | Cabello, Noemi | |
| dc.contributor.author | Olalla, Julián | |
| dc.contributor.author | Moreno, Santiago | |
| dc.contributor.author | Serrano-Villar, Sergio | |
| dc.date.accessioned | 2025-11-19T12:39:38Z | |
| dc.date.available | 2025-11-19T12:39:38Z | |
| dc.date.issued | 2023-09 | |
| dc.identifier.issn | 2352-3964 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/21161 | |
| dc.description.abstract | BACKGROUND: While a low CD4/CD8 ratio during HIV treatment correlates with immunosenescence, its value in identifying patients at an increased risk for clinical events remains unclear. METHODS: We analyzed data from the CoRIS cohort to determine whether CD4 count, CD8 count, and CD4/CD8 ratio at year two of antiretroviral therapy (ART) could predict the risk of serious non-AIDS events (SNAEs) during the next five years. These included major adverse cardiovascular events, non-AIDS-defining malignancies, and non-accidental deaths. We used pooled logistic regression with inverse probability weighting to estimate the survival curves and cumulative risk of clinical events. FINDINGS: The study included 4625 participants, 83% male, of whom 200 (4.3%) experienced an SNAE during the follow-up period. A CD4/CD8 ratio <0.3 predicted an increased risk of SNAEs during the next five years (OR 1.63, 95% CI 1.03-2.58). The effect was stronger at a CD4/CD8 ratio cut-off of <0.2 (OR 3.09, 95% CI 1.57-6.07). Additionally, low CD4 count at cut-offs of <500 cells/?L predicted an increased risk of clinical events. Among participants with a CD4 count ?500 cells/?L, a CD8 count ?1500 cells/?L or a CD4/CD8 ratio <0.4 predicted increased SNAE risk. INTERPRETATION: Our results support the use of the CD4/CD8 ratio and CD8 count as predictors of clinical progression. Patients with CD4/CD8 ratio <0.3 or CD8 count ?1500/?L, regardless of their CD4 count, may benefit from closer monitoring and targeted preventive interventions. FUNDING: This work was supported by CIBER (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU; by the Spanish AIDS Research Network (RIS) RD16/0025/0001 project as part of the Plan Nacional R + D + I, and cofinanced by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), ISCIII projects PI18/00154, PI21/00141, and ERDF, "A way to make Europe", ICI20/00058. | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER | |
| dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | CD4-CD8 Ratio | |
| dc.subject.mesh | Acquired Immunodeficiency Syndrome | |
| dc.subject.mesh | CD4 Lymphocyte Count | |
| dc.subject.mesh | Europe | |
| dc.subject.mesh | CD8-Positive T-Lymphocytes | |
| dc.title | Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 37639938 | |
| dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S2352396423003390 | |
| dc.identifier.doi | 10.1016/j.ebiom.2023.104773 | |
| dc.journal.title | Ebiomedicine |